{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:58Z","timestamp":1793973598452,"version":"4.8.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1905205"],"award-info":[{"award-number":["U1905205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in antiviral treatment-na\u00efve CHB patients. This study aimed to estimate the incidence of HCC in antiviral treatment-na\u00efve CHB patients who were treated with Entecavir (ETV) and Tenofovir Disoproxil Fumarate (TDF) and compare the efficacy of two treatment regimens in HCC reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PubMed, Embase, China National Knowledge Infrastructure, and Wanfang databases were systematically searched until June 24, 2021. The pooled incidence and 95% confidence interval of HCC were calculated by the Freeman-Tukey double arcsine transformation method. The efficacies of ETV and TDF treatments in HCC reduction were compared through a network meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 27 studies were identified as eligible for this systematic review. The incidence densities in the ETV and TDF treatment groups were 2.78 (95% CI: 2.21-3.40) and 2.59 (95% CI: 1.51-3.96) per 100 persons-year among patients with preexisting cirrhosis and 0.49 (95% CI: 0.32-0.68) and 0.30 (95% CI: 0.06-0.70) per 100 persons-year among patients without preexisting cirrhosis. As the proportion of CHB patients with preexisting cirrhosis increased, the incidence density of HCC also increased gradually. Compared with other Nucleos(t)ide analogs (NAs) treatments, ETV and TDF treatments significantly lowered the risk of HCC, with hazard ratios (HRs) of 0.60 (95% CI: 0.40-0.90) and 0.56 (95% CI: 0.35-0.89), respectively. However, there was no difference in the incidence density of HCC between ETV and TDF treatments (HR\u2009=\u20090.92, 95% CI: 0.71-1.20) regardless of preexisting cirrhosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ETV and TDF treatments were associated with significantly lower risks of HCC than other NAs treatments. However, no difference was observed between ETV and TDF treatments in the risk of HCC development regardless of preexisting cirrhosis among treatment-na\u00efve CHB patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09413-7","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T22:02:38Z","timestamp":1647554558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Risk of hepatocellular carcinoma in antiviral treatment-na\u00efve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Ze-Hong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Xian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Mei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Shao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"9413_CR1","unstructured":"Hepatitis B [https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b]. Accessed 23 Feb 2022."},{"issue":"2","key":"9413_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"12","key":"9413_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver Cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683\u201391.","journal-title":"JAMA Oncol"},{"issue":"1","key":"9413_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"issue":"4","key":"9413_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"key":"9413_CR6","unstructured":"Guiqiang W, Fusheng W, Hui Z, Taisheng L, Sujun Z, Hong Z, et al. Gulidelines for the prevention and treatment of chronic hepatitis B (version 2019). J Clin Hepatol. 2019;27(12):938\u201361."},{"issue":"4","key":"9413_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956\u201367.","journal-title":"J Hepatol"},{"issue":"2","key":"9413_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","volume":"53","author":"GV Papatheodoridis","year":"2010","unstructured":"Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348\u201356.","journal-title":"J Hepatol"},{"issue":"2","key":"9413_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/apt.12344","volume":"38","author":"AK Singal","year":"2013","unstructured":"Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013;38(2):98\u2013106.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"9413_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","volume":"19","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer. 2019;19(1):511.","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"9413_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jvh.12755","volume":"24","author":"SY Li","year":"2017","unstructured":"Li SY, Li H, Xiong YL, Liu F, Peng ML, Zhang DZ, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: a five-year observational cohort study. J Viral Hepat. 2017;24(Suppl 1):12\u201320.","journal-title":"J Viral Hepat"},{"key":"9413_CR12","doi-asserted-by":"crossref","unstructured":"Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut. 2020;69(7):1301\u20138.","DOI":"10.1136\/gutjnl-2019-318947"},{"key":"9413_CR13","doi-asserted-by":"crossref","unstructured":"Choi W-M, Choi J, Lim Y-S. Effects of Tenofovir vs Entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2021;19(2):246\u201358.e9.","DOI":"10.1016\/j.cgh.2020.05.008"},{"key":"9413_CR14","doi-asserted-by":"crossref","unstructured":"Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, et al. Comparative effectiveness of Entecavir vs Tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and Meta-analysis. Hepatology. 2021;73(1):68\u201378.","DOI":"10.1002\/hep.31267"},{"issue":"4","key":"9413_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000507253","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir treatment has lower risk of hepatocellular carcinoma than Entecavir treatment in patients with chronic hepatitis B: a systematic review and Meta-analysis. Liver Cancer. 2020;9(4):468\u201376.","journal-title":"Liver Cancer"},{"issue":"6","key":"9413_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamaoncol.2019.0576","volume":"5","author":"YS Lim","year":"2019","unstructured":"Lim YS, Ko MJ. Notice of retraction and replacement. Choi et al. risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5(1):30-36. JAMA Oncol. 2019;5(6):913\u20134.","journal-title":"JAMA Oncol"},{"issue":"9","key":"9413_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/eurheartj\/ehn106","volume":"29","author":"V Thijs","year":"2008","unstructured":"Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J. 2008;29(9):1086\u201392.","journal-title":"Eur Heart J"},{"issue":"4","key":"9413_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312\u201324.","journal-title":"Res Synth Methods"},{"key":"9413_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.","journal-title":"Br Med J"},{"issue":"9","key":"9413_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"9413_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: a Korean Nationwide cohort study. JAMA Oncol. 2019;5(1):30\u20136.","journal-title":"JAMA Oncol"},{"issue":"11-12","key":"9413_CR22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/apt.12990","volume":"40","author":"CS Coffin","year":"2014","unstructured":"Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40(11-12):1262\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9413_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/jvh.13485","volume":"28","author":"F G\u00fczelbulut","year":"2021","unstructured":"G\u00fczelbulut F, G\u00f6k\u00e7en P, Can G, Adal\u0131 G, De\u011firmenci Salt\u00fcrk AG, Bahad\u0131r \u00d6, et al. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat. 2021;28(5):826\u201336.","journal-title":"J Viral Hepat"},{"key":"9413_CR24","doi-asserted-by":"crossref","unstructured":"Ha I, Chung JW, Jang ES, Jeong SH, Kim JW. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: a propensity score matching analysis. J Gastroenterol Hepatol. 2020;35(10):1774\u201381.","DOI":"10.1111\/jgh.15031"},{"issue":"1","key":"9413_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98\u2013107.","journal-title":"Hepatology"},{"issue":"10","key":"9413_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/apt.15006","volume":"48","author":"YC Hsu","year":"2018","unstructured":"Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48(10):1128\u201337.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"9413_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","volume":"115","author":"YC Hsu","year":"2020","unstructured":"Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, et al. Tenofovir versus Entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B. Am J Gastroenterol. 2020;115(2):271\u201380.","journal-title":"Am J Gastroenterol"},{"key":"9413_CR28","doi-asserted-by":"crossref","unstructured":"Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. Clin Mol Hepatol. 2019;25(3):283\u201393.","DOI":"10.3350\/cmh.2018.0054"},{"issue":"3","key":"9413_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s10620-016-4431-8","volume":"62","author":"EJ Kim","year":"2017","unstructured":"Kim EJ, Yeon JE, Kwon OS, Lee HN, Shin SK, Kang SH, et al. Rapid alanine aminotransferase normalization with Entecavir and hepatocellular carcinoma in hepatitis B virus-associated cirrhosis. Dig Dis Sci. 2017;62(3):808\u201316.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"9413_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/jvh.12723","volume":"24","author":"GA Kim","year":"2017","unstructured":"Kim GA, Han S, Kim HD, An J, Lim YS. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response. J Viral Hepat. 2017;24(11):990\u20137.","journal-title":"J Viral Hepat"},{"issue":"2","key":"9413_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66(2):335\u201343.","journal-title":"Hepatology"},{"issue":"3","key":"9413_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","volume":"71","author":"SU Kim","year":"2019","unstructured":"Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea. J Hepatol. 2019;71(3):456\u201364.","journal-title":"J Hepatol"},{"issue":"3","key":"9413_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3350\/cmh.2016.0021","volume":"22","author":"J Lee","year":"2016","unstructured":"Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, et al. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol. 2016;22(3):339\u201349.","journal-title":"Clin Mol Hepatol"},{"issue":"05","key":"9413_CR34","first-page":"287","volume":"25","author":"L Lei","year":"2012","unstructured":"Lei L, Wei L, Yuhan C, Peng L, Feili W, Chunlei F, et al. Increased incidence of hepatocellular carcinoma due to antiviral drug resistance in patients with hepatitis B-related ecompensated cirrhosis. Infect Dis Inform. 2012;25(05):287\u201391.","journal-title":"Infect Dis Inform"},{"key":"9413_CR35","first-page":"434","volume":"34","author":"L Yi","year":"2013","unstructured":"Yi L. Observation on the incidence of primary liver cancer after chronic hepatitis B patients treated with Entecavir and Adefovir. Guide China Med. 2013;34:434\u20135.","journal-title":"Guide China Med"},{"issue":"1","key":"9413_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.gastro.2014.02.033","volume":"147","author":"YS Lim","year":"2014","unstructured":"Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147(1):152\u201361.","journal-title":"Gastroenterology"},{"issue":"6","key":"9413_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3748\/wjg.v24.i6.725","volume":"24","author":"TC Lin","year":"2018","unstructured":"Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, et al. Clinical utility of hepatitis B surface antigen kinetics in treatment-naive chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol. 2018;24(6):725\u201336.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"9413_CR38","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","volume":"18","author":"H Oh","year":"2020","unstructured":"Oh H, Yoon EL, Jun DW, Ahn SB, Lee HY, Jeong JY, et al. No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with Entecavir vs Tenofovir. Clin Gastroenterol Hepatol. 2020;18(12):2793\u2013802.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"9413_CR39","first-page":"966","volume":"33","author":"O Ying","year":"2011","unstructured":"Ying O, Wei L, Yuhan C, Feili W, Lei L, Chunlei F, et al. Comparing the efficacy of monotherapy versus combination therapy of nucleos(t)ide analogues for decompensated HBV liver cirrhosis. Beijing Med J. 2011;33(12):966\u20139.","journal-title":"Beijing Med J"},{"issue":"4","key":"9413_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12072-020-10031-3","volume":"14","author":"FM Sou","year":"2020","unstructured":"Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, et al. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020;14(4):513\u201320.","journal-title":"Hepatol Int"},{"key":"9413_CR41","first-page":"10","volume":"10","author":"JW Shin","year":"2020","unstructured":"Shin JW, Jeong J, Jung SW, Lee SB, Park BR, Kim MJ, et al. Comparable incidence of hepatocellular carcinoma in chronic hepatitis B patients treated with Entecavir or Tenofovir. Dig Dis Sci. 2020;10:10.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"9413_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3350\/cmh.2016.0086","volume":"23","author":"W Sohn","year":"2017","unstructured":"Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, et al. Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol. 2017;23(2):170\u20138.","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"9413_CR43","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/liv.13253","volume":"36","author":"TH Su","year":"2016","unstructured":"Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36(12):1755\u201364.","journal-title":"Liver Int"},{"issue":"7","key":"9413_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmi.2017.02.001","volume":"23","author":"IT Wu","year":"2017","unstructured":"Wu IT, Hu TH, Hung CH, Lu SN, Wang JH, Lee CM, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017;23(7):464\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"9413_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","volume":"158","author":"TC Yip","year":"2020","unstructured":"Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir is associated with lower risk of hepatocellular carcinoma than Entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158(1):215\u201325 e216.","journal-title":"Gastroenterology"},{"issue":"11","key":"9413_CR46","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hepr.13194","volume":"48","author":"JH Yu","year":"2018","unstructured":"Yu JH, Jin YJ, Lee JW, Lee DH. Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir\/tenofovir in South Korea. Hepatol Res. 2018;48(11):862\u201371.","journal-title":"Hepatol Res"},{"issue":"2","key":"9413_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3449","volume":"13","author":"A Arzumanyan","year":"2013","unstructured":"Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123\u201335.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"9413_CR48","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3748\/wjg.14.1652","volume":"14","author":"DY But","year":"2008","unstructured":"But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1652\u20136.","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"9413_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1440-1746.2010.06546.x","volume":"26","author":"MC Kew","year":"2011","unstructured":"Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(Suppl 1):144\u201352.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"9413_CR50","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5009\/gnl18546","volume":"14","author":"X Wang","year":"2020","unstructured":"Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, et al. Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and Meta-analysis. Gut Liver. 2020;14(2):232\u201347.","journal-title":"Gut Liver"},{"issue":"10","key":"9413_CR51","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/jgh.15078","volume":"35","author":"CH Tseng","year":"2020","unstructured":"Tseng CH, Tseng CM, Wu JL, Hsu YC, El-Serag HB. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking Entecavir or Tenofovir therapy: a systematic review. J Gastroenterol Hepatol. 2020;35(10):1684\u201393.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"9413_CR52","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17474124.2017.1361822","volume":"11","author":"M Okada","year":"2017","unstructured":"Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11(12):1095\u2013104.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"114","key":"9413_CR53","doi-asserted-by":"publisher","first-page":"477","DOI":"10.5754\/hge11426","volume":"59","author":"F Guzelbulut","year":"2012","unstructured":"Guzelbulut F, Ovunc AO, Oetinkaya ZA, Senates E, Gokden Y, Salturk AG, et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepatogastroenterology. 2012;59(114):477\u201380.","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"9413_CR54","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886\u201393.","journal-title":"Hepatology"},{"issue":"5","key":"9413_CR55","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","volume":"60","author":"M Buti","year":"2015","unstructured":"Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457\u201364.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"9413_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","volume":"14","author":"M Li","year":"2020","unstructured":"Li M, Lv T, Wu S, Wei W, Wu X, Ou X, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int. 2020;14(1):105\u201314.","journal-title":"Hepatol Int"},{"issue":"9","key":"9413_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jgh.15036","volume":"35","author":"L Gu","year":"2020","unstructured":"Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35(9):1467\u201376.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"9413_CR58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","volume":"5","author":"CH Tseng","year":"2020","unstructured":"Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9413_CR59","doi-asserted-by":"crossref","unstructured":"Yuan BH, Li RH, Huo RR, Li MJ, Papatheodoridis G, Zhong JH. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. J Gastroenterol Hepatol. 2022 (Online ahead of print)","DOI":"10.1111\/jgh.15783"},{"issue":"5","key":"9413_CR60","doi-asserted-by":"publisher","first-page":"7147","DOI":"10.18632\/aging.202573","volume":"13","author":"J Yuan","year":"2021","unstructured":"Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging. 2021;13(5):7147\u201365.","journal-title":"Aging"},{"issue":"10","key":"9413_CR61","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2019-320326","volume":"69","author":"YX Teng","year":"2020","unstructured":"Teng YX, Li MJ, Xiang BD, Zhong JH. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Gut. 2020;69(10):1900\u20132.","journal-title":"Gut"},{"issue":"2","key":"9413_CR62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jvh.13418","volume":"28","author":"J Lee","year":"2021","unstructured":"Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: a nationwide cohort study. J Viral Hepat. 2021;28(2):353\u201363.","journal-title":"J Viral Hepat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09413-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09413-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:05:08Z","timestamp":1666569908000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09413-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9413"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09413-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the author declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}